国家: 新加坡
语言: 英文
来源: HSA (Health Sciences Authority)
TINZAPARIN SODIUM
LEO PHARMA ASIA PTE LTD
B01AB10
3500 axa iu/0.35 ml
INJECTION
TINZAPARIN SODIUM 3500 axa iu/0.35 ml
SUBCUTANEOUS
Prescription Only
LABORATOIRES LEO
ACTIVE
1999-02-09
INNOHEP® ANTICOAGULANT Tinzaparin sodium VIALS OF 2 ML Tinzaparin sodium 10,000 anti-Xa IU/ml, preserved with benzyl alcohol. Tinzaparin sodium 20,000 anti-Xa IU/ml, preserved with benzyl alcohol, stabilized with sodium metabisulphite. SYRINGE OF 0.35 ML AND 0.45ML Tinzaparin sodium 10,000 anti-Xa IU/ml. SYRINGE OF 0.5 ML AND 0.7ML Tinzaparin sodium 20,000 anti-Xa IU/ml, stabilized with sodium metabisulphite. Not all presentations listed above are available locally. PROPERTIES Tinzaparin sodium is a low molecular weight heparin produced by enzymatic depolymerization of conventional heparin. The molecular mass is between 1,000 and 14,000 dalton, with a peak maximum molecular mass of approx. 4,500 dalton. Tinzaparin sodium is an anti-thrombotic agent. INNOHEP ® has a bioavailability of about 90% following subcutaneous injection. The absorption half-life is 200 minutes, peak plasma activity being observed after 4–6 hours. The elimination half-life is about 80 minutes. Tinzaparin sodium is eliminated, primarily with the urine, as unchanged drug. The pharmacokinetics/pharmacodynamics of INNOHEP ® are monitored by anti-Xa activity. There is a linear dose-response relationship between plasma activity and the dose administered. The biological activity of INNOHEP ® is expressed in anti-Xa international units. INDICATIONS Treatment of deep-vein thrombosis. Treatment of pulmonary embolism. Prevention of postoperative deep-vein thrombosis in patients undergoing general and orthopaedic surgery. Prevention of clotting in in-dwelling intravenous lines for extracorporeal circulation and haemodialysis. DOSAGE Treatment of DVT: The recommended dose is 175 anti-Xa IU/kg body-weight s.c. once daily. Treatment of pulmonary embolism: The recommended dose is 175 anti-Xa IU/kg body-weight s.c.once daily. Thromboprophylaxis in patients with moderate risk of t 阅读完整的文件
INNOHEP® ANTICOAGULANT Tinzaparin sodium VIALS OF 2 ML Tinzaparin sodium 10,000 anti-Xa IU/ml, preserved with benzyl alcohol. Tinzaparin sodium 20,000 anti-Xa IU/ml, preserved with benzyl alcohol, stabilized with sodium metabisulfite. SYRINGE OF 0.35 ML AND 0.45ML Tinzaparin sodium 10,000 anti-Xa IU/ml. SYRINGE OF 0.5 ML AND 0.7ML Tinzaparin sodium 20,000 anti-Xa IU/ml, stabilized with sodium metabisulfite. Not all presentations listed above are available locally. PROPERTIES Tinzaparin sodium is a low molecular weight heparin produced by enzymatic depolymerization of conventional heparin. The molecular mass is between 1,000 and 14,000 dalton, with a peak maximum molecular mass of approx. 4,500 dalton. Tinzaparin sodium is an anti-thrombotic agent. INNOHEP ® has a bioavailability of about 90% following subcutaneous injection. The absorption half-life is 200 minutes, peak plasma activity being observed after 4–6 hours. The elimination half-life is about 80 minutes. Tinzaparin sodium is eliminated, primarily with the urine, as unchanged drug. The pharmacokinetics/pharmacodynamics of INNOHEP ® are monitored by anti-Xa activity. There is a linear dose-response relationship between plasma activity and the dose administered. The biological activity of INNOHEP ® is expressed in anti-Xa international units. INDICATIONS Treatment of deep-vein thrombosis. Treatment of pulmonary embolism. Prevention of postoperative deep-vein thrombosis in patients undergoing general and orthopaedic surgery. Prevention of clotting in in-dwelling intravenous lines for extracorporeal circulation and haemodialysis. DOSAGE Treatment of DVT: The recommended dose is 175 anti-Xa IU/kg body-weight s.c. once daily. Treatment of pulmonary embolism: The recommended dose is 175 anti-Xa IU/kg body-weight s.c.once daily. Thromboprophylaxis in patients with moderate risk of thrombosis (general surgery): On the day of operation 3,500 anti-Xa IU s.c. 2 hours before surgery and postoperatively once daily 3,500 anti-Xa IU for 7–10 days. Thromboprophyla 阅读完整的文件